Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
25.13
-0.17 (-0.67%)
At close: Sep 2, 2026, 4:00 PM EDT
25.20
+0.07 (0.28%)
Pre-market: Sep 3, 2026, 5:15 AM EDT

Tyra Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
34.1429.8324.117.4315.925.65
Research & Development
126.32102.9380.0862.5243.0120.64
Operating Expenses
160.46132.76104.1879.9558.9326.29
Operating Income
-160.46-132.76-104.18-79.95-58.93-26.29
Interest & Investment Income
11.912.8217.710.813.650.01
Other Non Operating Income (Expenses)
-----0.05-0.02
Pretax Income
-148.57-119.95-86.48-69.13-55.33-26.29
Net Income
-148.57-119.95-86.48-69.13-55.33-26.29
Net Income to Common
-148.57-119.95-86.48-69.13-55.33-26.29
Net Income Growth
------
Shares Outstanding (Basic)
626057434214
Shares Outstanding (Diluted)
626057434214
Shares Change
4.40%4.17%33.98%1.96%203.94%793.58%
EPS (Basic)
-2.40-2.01-1.51-1.62-1.32-1.91
EPS (Diluted)
-2.40-2.01-1.51-1.62-1.32-1.91
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-109.9-95.28-70.44-50.91-50.84-24.41
Free Cash Flow Per Share
-1.78-1.60-1.23-1.19-1.21-1.77
EBITDA
-159.92-132.22-103.66-79.59-58.63-26.15
D&A For EBITDA
0.540.550.520.360.30.14
EBIT
-160.46-132.76-104.18-79.95-58.93-26.29
SEC Filings: 10-K · 10-Q